Ascelia Pharma AB
7ZA
Company Profile
Business description
Ascelia Pharma AB is a biotech company focused on orphan oncology treatments. The company develops and commercializes novel drugs that address unmet medical needs and have a clear development and market pathway. It has two drug candidates, Orviglance and Oncoral, in development. Orviglance (manganese chloride tetrahydrate) is an oral contrast agent for MR imaging developed to improve the detection and visualization of focal liver lesions (including liver metastases and primary tumors) in patients with impaired kidney function, and Oncoral is a novel oral irinotecan tablet in development.
Contact
Hyllie Boulevard 34
Malmo215 32
SWET: +46 735179118
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2026
Employees
10
Stocks News & Analysis
stocks
Do AI labs like Anthropic and OpenAI have economic moats?
Leading AI labs are building economic moats to stave off commodification threats.
stocks
12 picks for an income portfolio - Q3 2026 update
Passive income growth continues to be strong but two picks are facing challenges.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,937.00 | 59.30 | 0.67% |
| CAC 40 | 7,843.03 | 39.70 | 0.51% |
| DAX 40 | 25,223.02 | 135.75 | 0.54% |
| Dow JONES (US) | 51,654.95 | 423.31 | 0.83% |
| FTSE 100 | 10,612.85 | 60.80 | 0.58% |
| HKSE | 24,245.14 | 33.79 | 0.14% |
| NASDAQ | 27,366.17 | 172.83 | 0.64% |
| Nikkei 225 | 69,030.92 | 11.19 | -0.02% |
| NZX 50 Index | 13,827.62 | 78.27 | 0.57% |
| S&P 500 | 7,811.54 | 46.18 | 0.59% |
| S&P/ASX 200 | 8,783.20 | 66.60 | 0.76% |
| SSE Composite Index | 3,797.24 | 16.55 | -0.43% |